UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
This guide analyzes beta values across leading coins to identify those with the lowest market sensitivity. Explore interpretation and strategy tips.
26,241 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Mastercard launches a digital, AI-powered Virtual CFO to deliver CFO-grade guidance to small businesses, addressing a...
As SuRo Capital releases its Q4 2025 results, investors need a clear playbook. This deep dive breaks down the key met...
Minnesota’s business elite issued a restrained message on immigration enforcement that drew sharp critique and raised...
A growing cohort of retirees is quietly collecting income from dividend-rich UK stocks, using low-cost funds that bun...
A career setback in 1998 launched Jamie Dimon's rise to the helm of JPMorgan Chase. This piece draws lessons for pers...
A federal judge blocked DOJ subpoenas aimed at Fed Chair Powell over a congressional hearing on the central bank’s HQ...
Could buying sweetgreen stock be a gateway to lasting wealth, or is it a risky turnaround bet? This guide cuts throug...
Oil sits near $102 per barrel in mid-March 2026 as markets digest supply discipline, demand recovery, and policy move...
Discover how Marek Capital's co-founder approaches credit, risk, and portfolio design. This practical, investor-focus...
Gas prices are climbing despite the U.S. being the world's leading producer of oil. Industry officials point to refin...
NVIDIA has traded in a tight range for months despite strong earnings. New orders from China could lift the stock if ...